GoodRx announced a collaboration with Currax Pharmaceuticals LLC to launch a national access program for Contrave® (naltrexone HCl/bupropion HCl), an FDA-approved oral weight loss medication. This partnership makes Contrave available at a cash price of $199 via GoodRx.
The program aims to expand access to affordable weight management medication for patients, regardless of their insurance status, at over 70,000 pharmacies across the United States. This addresses the challenge that over 40% of U.S. adults live with obesity, often facing cost and coverage barriers to effective treatment.
By combining Currax's clinical leadership in obesity care with GoodRx's platform, this collaboration removes a major financial barrier for patients. It helps more individuals take control of their health by accessing a life-changing medication at a reduced cost.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.